Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Официальное название

Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )

Обзор

The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.

Вмешательства

• Биопрепарат Ublituximab
  Administered as an intravenous (IV) infusion.
• Препарат Placebo
  IV infusion

Первичные конечные точки

• Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 [Срок оценки: Baseline up to Week 48]
• Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab [Срок оценки: Predose and at multiple timepoints up to Week 16]

Вторичные конечные точки (3)

• Parts A: Percentage of Participants Free of T1 Gd-Enhancing Lesions [Срок оценки: Week 48]
• Parts A and B: Percentage of Participants Experiencing Infusion Related Reactions (IRRs) [Срок оценки: Up to Week 48]
• Parts A: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores [Срок оценки: Part A: Baseline, Week 24 and Week 48]

Критерии участия

Критерии включения

• Diagnosis of RMS (2017 Revised McDonald criteria).
• Participants must meet one of the following prior treatment definitions:

• Participants naïve to treatment.
• Participants previously treated with a disease modifying therapy (DMT) who have discontinued treatment prior to consent and meet the washout requirements.
• Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.
• Neurologically stable for > 30 days prior to first dose of ublituximab.
• Female participants of childbearing potential must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 6 months after the last dose of ublituximab.
• Part C: participants currently treated with an anti-CD20 agent for at least 6 months and meet the washout requirements prior to W1D1.
• Part C: Discontinuation of current anti-CD20 must be due to suboptimal experience

Критерии исключения

• History of any serious 3 Infusion Related Reaction (IRR) on prior anti-CD20 therapy.
• Primary-progressive multiple sclerosis (PPMS) or inactive Secondary Progressive MS (SPMS).
• Active chronic (or stable but treated with immune therapy) disease of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).
• Current evidence or known history of clinically significant infection, including: chronic, recurrent, or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment such as, but not limited to chronic urinary tract infection, chronic pulmonary infection with bronchiectasis, tuberculosis, or active hepatitis C virus (HCV).
• Previous serious opportunistic or atypical infection.
• Evidence of chronic active or history of hepatitis B virus (HBV) infection as evidenced by a detectable hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb), or chronic hepatitis C infection. Participants with positive hepatitis C virus antibody (HCV Ab) are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
• History or evidence (clinical, radiological, or biomarker) of suspected or confirmed progressive multifocal leukoencephalopathy (PML).
• Receipt of any live or live-attenuated vaccines (including vaccines for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration.
• Participants requiring treatment with intravenous immune globulin (IVIG) for decreased immunoglobulins within the 12 months prior to W1D1.
• Any active malignancies other than adequately treated basal, squamous cell or in situ carcinoma.
• Participants who have ever received ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab (including for non-MS indications).

Note: Other Inclusion/Exclusion criteria may apply.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Двойное слепое

Основная цель

Лечение

Центры проведения

США · 36 центров

• TG Therapeutics Investigational Trial Site — Birmingham
• TG Therapeutics Investigational Trial Site — Cullman
• TG Therapeutics Investigational Trial Site — Orange
• TG Investigational Site — Fort Collins
• TG Therapeutics Investigational Trial Site — Washington D.C.
• TG Therapeutics Investigational Trial Site — Tampa
• TG Therapeutics Investigational Trial Site — Savannah
• TG Therapeutics Investigational Trial Site — Chicago
• … и ещё 28 центров

Польша · 11 центров

• TG Therapeutics Investigational Trial Site — Bydgoszcz
• TG Therapeutics Investigational Trial Site — Katowice
• TG Therapeutics Investigational Trial Site — Katowice
• TG Therapeutics Investigational Trial Site — Kielce
• TG Therapeutics Investigational Trial Site — Krakow
• TG Therapeutics Investigational Trial Site — Lodz
• TG Therapeutics Investigational Trial Site — Olsztyn
• TG Therapeutics Investigational Trial Site — Poznan
• … и ещё 3 центра

Идентификаторы

NCT: NCT05877963 · TG1101-RMS401 · 2024-519284-18-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗